ZURICH (Reuters) – Roche’s bid to muscle in on Shire’s share of the $11 billion hemophilia drug market took a new, contentious turn this weekend when the British drugmaker won a court injunction against how the Swiss drugmaker talks about its new medicine.

Read More At Article Source | Article Attribution